96 Tests PN: B113340

Components:

45x Ab-conjugated beads (S4P3- Human CD73 Ab-bead). PN: B113340A. One vial containing 100 µL of anti-human CD73 conjugated to AimPlex Bead S4P3.

25x Biotin-detection Ab (Human CD73 Biotin-dAb). PN: B113340B. One vial containing 100 µL of biotinylated anti-Human CD73.

Lyophilized Standard Mix - Human CD73. PN: B113340S. One vial containing lyophilized CD73.

Application: Optimal antibody pair and antigen standard for assaying human Human CD73. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 70 pg/mL

  • Quantitation range:

  • LLOQ: < 150 pg/mL

  • ULOQ: > 20,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

CD73, also known as ecto-5′-nucleotidase or 5′-nucleotidase (5′-NT), is an enzyme that in humans is encoded by the NT5E gene.  NT5E (CD73) is a surface enzyme which is expressed on multiple cells. This enzyme mediates the gradual hydrolysis of the autocrine and paracrine danger signals of ATP and ADP to anti-inflammatory adenosine. The enzyme is used as a marker of lymphocyte differentiation.  A deficiency of CD73 occurs in a variety of immunodeficiency diseases. Some tumors have upregulation and overexpression of CD73.  Together with PD-1 and CTLA-4, CD73 has been proposed as a drug target for cancer immune checkpoint therapy. In some cases of lupus patients, adequate T cell expression of CD73 is missing, which shows an impaired regulatory function of T cells.

 References:

1.      Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y (August 1990). "Primary structure of human placental 5'-nucleotidase and identification of the glycolipid anchor in the mature form". European Journal of Biochemistry. 191 (3): 563–9. doi:10.1111/j.1432-1033.1990.tb19158.x. PMID 2129526.

2.      Luca Antonioli, Gennady G Yegutkin, Pál Pacher, Corrado Blandizzi, György Haskó (2016). "Anti-CD73 in cancer immunotherapy: awakening new opportunities". Trends Cancer 2016 Feb 1;2(2):95-109. PMID: 27014745 PMCID: PMC4800751 DOI: 10.1016/j.trecan.2016.01.003.

3.      Knight JS, Mazza LF, Yalavarthi S, Sule G, Ali RA, Hodgin JB, et al. (2018). "Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction". Frontiers in Immunology. 9: 1322. doi:10.3389/fimmu.2018.01322. PMC 6004379. PMID 29942314.

4.      Goswami et al. (2019). “Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma” Nature Medicine. 26: 39. doi: 10.1038/s41591-019-0694-x